BEIJING, March 24, 2017 /PRNewswire/ -- Sinovac Biotech
Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider
of biopharmaceutical products in China, today announced that its board of
directors has amended its shareholder rights plan. The
amendment extends the expiration date of the plan from March 27, 2017 to March
27, 2018. The amendment was not in response to any
acquisition proposal.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines
against hepatitis A and B, seasonal influenza, H5N1 pandemic
influenza (avian flu), H1N1 influenza (swine flu), mumps and canine
rabies. In 2009, Sinovac was the first company worldwide to
receive approval for its H1N1 influenza vaccine, which it has
supplied to the Chinese Government's vaccination campaign and
stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government stockpiling
program. Sinovac' s newly developed
innovative vaccine against HFMD caused by EV71 was commercially
launched in 2016. The Company is currently developing a
number of new products including a Sabin-strain inactivated polio
vaccine, pneumococcal polysaccharides vaccine, pneumococcal
conjugate vaccine and varicella vaccine. Sinovac primarily sells
its vaccines in China, while also
exploring growth opportunities in international markets. The
Company has exported select vaccines to countries in Asia and South
America. For more information, please visit the Company's
website www.sinovac.com.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S.: 1-646-308-1707
Email: william.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-amends-shareholder-rights-plan-300428948.html
SOURCE Sinovac Biotech Co., Ltd.